EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Integrating Metabolic Modulation and Nanomedicine for Cancer Immunotherapy

Xiaosu Zhou, Ruibing Deng, Zunde Liao, Xiaoyu Huang, Junting Huang, Hanlou Yang, Kam W Leong iD, Yiling Zhong iD

Advanced Science · 2025-10 · 12 (40)

DOI: 10.1002/advs.202510004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 12.09.2025. Verfasst von Xiaosu Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, Guangdong, 511443, China. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Nanomedicine, Tumor Microenvironment. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 439 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, The National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer cells undergo significant metabolic reprogramming to support rapid growth, survival under stress, and resistance to therapies. As our understanding of tumor metabolism and the tumor microenvironment (TME) deepens, there is growing interest in exploiting metabolic vulnerabilities as therapeutic strategies. This review explores key alterations in metabolic pathways, including glucose, amino acid, lipid, nucleotide metabolism, and mitochondrial function, and highlights their impact on tumor progression, the TME, and immune cell function. In addition, the review discusses emerging strategies aimed at targeting these metabolic pathways with a focus on nanomaterial‐based therapies. This includes the use of nanoparticles and drug delivery systems designed to modulate immunometabolism within cancer. These innovative approaches aim to reprogram the TME, enhance immune responses, and improve the targeted delivery of therapeutic agents to tumor sites, offering new ways to overcome conventional therapeutic resistance. Finally, the review also addresses the foreseeable challenges and potential future developments in this field, outlining the opportunities and obstacles that must be addressed for the clinical translation of these strategies in cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmunotherapyNanomedicineTumor MicroenvironmentHumansDrug Delivery SystemsNanoparticlesAnimals

Stichwörter der Autor:innen

immunometabolismimmunotherapymetabolic reprogrammingnanomedicinetumor microenvironment

Autor:innen und Institutionen

  • College of Pharmacy, State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, Guangdong, 511443, China.
  • Department of Biomedical Engineering, Columbia University, New York, NY, 10027, United States.

ORCID-Profile: Kam W Leong, Yiling Zhong

Förderung

  • Basic and Applied Basic Research Foundation of Guangdong Province
  • The National Natural Science Foundation of China

Zitieren

APA

Zhou, X., Deng, R., Liao, Z., Huang, X., Huang, J., Yang, H., Leong, K. W., & Zhong, Y. (2025). Integrating Metabolic Modulation and Nanomedicine for Cancer Immunotherapy. Advanced Science, 12(40). https://doi.org/10.1002/advs.202510004

Vancouver

Zhou X, Deng R, Liao Z, Huang X, Huang J, Yang H, et al. Integrating Metabolic Modulation and Nanomedicine for Cancer Immunotherapy. Advanced Science. 2025;12(40). doi:10.1002/advs.202510004

BibTeX
@article{Zhou2025,
  author = {Zhou, Xiaosu and Deng, Ruibing and Liao, Zunde and Huang, Xiaoyu and Huang, Junting and Yang, Hanlou and Leong, Kam W and Zhong, Yiling},
  title = {Integrating Metabolic Modulation and Nanomedicine for Cancer Immunotherapy},
  journal = {Advanced Science},
  year = {2025},
  volume = {12},
  number = {40},
  doi = {10.1002/advs.202510004}
}
Kostenlos starten →